Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial

Ann Emerg Med. 2021 May;77(5):555. doi: 10.1016/j.annemergmed.2020.12.016.

Authors

Ghina Moussa¹, Madeleine Genest², Eric Villeneuve², Josh J Wang³

Affiliations

¹ Faculty of Pharmacy, Université de Montréal, Montreal, Quebec, Canada, Department of Pharmacy, McGill University Health Centre, Montreal, Quebec, Canada.
² Department of Pharmacy, McGill University Health Centre, Montreal, Quebec, Canada.
³ Department of Emergency Medicine, McGill University, Montreal, Quebec, Canada, Centre Antipoison du Québec, Québec, Quebec, Canada.

PMID: 33902836
DOI: 10.1016/j.annemergmed.2020.12.016

No abstract available

Publication types

Letter
Comment

MeSH terms

Antiemetics* / therapeutic use
Cannabis*
Female
Haloperidol / therapeutic use
Humans
Hyperemesis Gravidarum* / drug therapy
Ondansetron / therapeutic use
Pregnancy
Vomiting / chemically induced
Vomiting / drug therapy

Substances

Antiemetics
Ondansetron
Haloperidol